Ependymoblastoma

3 clinical trials · Condition

Record	Firm	Date
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 (NCT01082926)	City of Hope Medical Center	2010-05-01
An Intermediate Expanded Use Trial of DFMO (NCT03581240)	Giselle Sholler

Every clearance here is in the API, with alerts when new ones post.